Skip to main content

Advertisement

Table 1 Patient demographic and dabigatran dosing characteristics

From: Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting

Characteristic Value
Mean Age ± SD (years) 81.3 ± 4.5
Female (%) 44.5
Mean time after last dabigatran dose ± SD (hours) 13.1 ± 2.3
Mean weight ± SD (kg) 83.0 ± 21.1
Body mass index ± SD (kg/m2) 28.9 ± 4.7
Baseline Renal Clearance ± SD (mL/min)  
 Cockcroft-Gault 68.4 ± 28.4
 CKD-EPI 40.9 ± 12.3
Dabigatran dosage, n (%)  
 75 mg twice daily 4 (44.4)
 150 mg twice daily 5 (55.6)
Cormorbidities (n, %)  
 Chronic obstructive pulmonary disease 3 (33.3)
 Diabetes Mellitus 4 (44.4)
 Heart Failure 3 (33.3)
 Malignancy 2 (22.2)
 Thyroid Disease 4 (44.4)
 Coronary Artery Disease 2 (22.2)
Mean HPLC-MS/MS dabigatran level ± SD (ng/mL)a 161.1 ± 104.1
Mean chromogenic anti-IIa dabigatran level ± SD (ng/mL)a 161.9 ± 104.8
  1. aPooled data from all office visits